Childhood Trauma in Patients With PAH—Prevalence, Impact on QoL, and Mental Health—A Preliminary Report

Da-Hee Park1,2†, Tanja Meltendorf3†, Kai G. Kahl3, Jan C. Kamp1,2, Manuel J. Richter4,5, Henning Gall4,5, Hossein A. Ghofrani4,5, Marius M. Hoeper1,2, Karen M. Olsson1,2† and Jan Fuge1,2†

1 Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 2 Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover, Germany, 3 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany, 4 Department of Internal Medicine, Justus Liebig University Giessen, Giessen, Germany, 5 German Center for Lung Research, Universities of Giessen and Marburg Lung Center, Giessen, Germany

Background/Objective: Child maltreatment is associated with increased risk of psychological consequences, contributes to morbidity and has long lasting effects on mental health and quality of life. Child maltreatment has not been assessed in patients with pulmonary arterial hypertension (PAH). We examined the prevalence of child maltreatment and determined their impact on disease severity in patients with PAH.

Methods: A cross-sectional observational multicenter study at two PH centers in Germany was conducted. Patients with a confirmed diagnosis of PAH were given a self-administered questionnaire. Child maltreatment using the Childhood Trauma Questionnaire (CTQ), quality of life (QoL), anxiety, depression, and lifestyle factors were assessed and enhanced by clinical parameters 6-min walk distance (6MWD), WHO functional class (WHO FC), and serum levels of N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP). Prevalence rates of child maltreatment were compared to the general population and impact of child maltreatment on disease severity was calculated by logistic regression analysis.

Results: Two-hundred and seventeen patients, 71% female and a median age of 56 years were enrolled in this study. Patients with PAH had higher rates of emotional abuse and lower rates of physical neglect compared to the German population while rates of emotional neglect, physical abuse, and sexual abuse did not differ between patients and German population. Patients with any form of child maltreatment were more likely to be active smokers, had a worse QoL and more anxiety or depression. Moderate associations between child maltreatment, mental health, QoL, lifestyle factors and clinical parameters could be observed. Logistic regression analysis showed a significant impact of CTQ-total score on disease severity with an OR of 1.022 (95%-CI: 1.001–1.042, p = 0.035).

Conclusion: We found a higher rate of child maltreatment in patients with PAH in comparison to the German population. Correlations suggest moderate associations
INTRODUCTION

Pulmonary arterial hypertension (PAH) is progressive pulmonary vascular disease. Characterized by remodeling of pulmonary vasculature it leads to increased pulmonary vascular resistance (1, 2). Patients with PAH are experiencing symptoms such as dyspnea on exertion, fatigue and with disease progression potentially clinical signs of heart failure. These debilitating symptoms impair physical activities and quality of life (QoL) (3, 4). While the disease remains fatal as none of the currently available drugs are curative, improvement of therapeutic options, clinical outcomes and life expectancy have put questions of patient’s quality of life, mental health, emotional, and social burden are on the forefront of current research (5–8). Data on prevalence of psychiatric disorders in PAH patients (9, 10) is still scarce. Olsson et al. demonstrated a higher prevalence of anxiety and depression disorders with negative impact on QoL in PAH compared to levels in the German population (11, 12). Child maltreatment may pose an additional risk factor associated with lower QoL and mental disorders in patients with PAH. Several studies have identified child maltreatment as an important contributing factor to the incidence and severity of depressive disorders (13). Child maltreatment is defined as the abuse and neglect against a child under the age of 18 by a parent or other caregivers. It includes all types of physical and/or emotional ill-treatment, sexual abuse and neglect which results in actual or potential harm to the child’s health, survival, development, or dignity in the context of a relationship of responsibility, trust, or power (14). It has been associated with poorer overall health, greater physical, and emotional functional disability and higher degree of health risk behavior. Patients with multiple types of maltreatment showed greatest worsening of self-reported health symptoms (15). Child maltreatment is associated with various diseases such as the development of cardiovascular diseases, type 2 diabetes or chronic obstructive pulmonary diseases leading to higher mortality (16–18). Proskynitopoulos et al. (19) found increased prevalence of child maltreatment in adults with congenital heart disease compared to the general German population. Higher total Child trauma questionnaire (CTQ) scores correlated with decreased quality of life, higher rates of anxiety, and depression and contributed to the prediction of New York Heart Association (NYHA) scores (19). The present study aimed to assess the (i) prevalence of child maltreatment in patients with PAH and (ii) to compare this with the prevalence in the German general public as well as (iii) to assess the impact, differences and associations of child maltreatment on disease severity, lifestyle factors, mental health, and QoL in patients with PAH.

METHODS

This cross-sectional observational multicentre study included patients with a confirmed diagnosis of PAH at two participating PH referral centers (Hannover Medical School and University of Giessen and Marburg, both in Germany). The study concept was developed in cooperation with patient organizations as suggested during the latest Pulmonary Hypertension World Symposium in 2018 (20). All patients gave written informed consent. The study was approved by local institutional review boards (Nr. 8540_BO_K_2019 for Hannover and Nr. 21119 for Giessen and Marburg). Patients were contacted between September 2019 and March 2020. This study was conducted by a self-administrated questionnaire.

Patient Setting and Clinical Parameters

Patients were selected based on diagnosis of PAH according to current criteria (1) and age ≥ 18 years. Assessment included hemodynamics from right heart catheterization at time of diagnosis, 6-minute walk distance (6MWD), WHO functional class (FC), and serum levels of N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP). Risk assessment for our cohort was based on three variables FC, 6MWD, and BNP/NT-proBNP as previously described (21, 22). Each variable was graded with a number as low risk (1), intermediate risk (2), and high risk (3). The average risk was calculated by dividing the sum of the grades by the number of available variables and rounding to the next integer (23).

Assessment of Child Maltreatment

Child maltreatment was assessed using the German version of the Childhood Trauma Questionnaire CTQ (24). The CTQ consists of a 28-item self-rating scale divided in five subscales inquiring five areas: emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect. The items are rated from 1 (never true) to 5 (very often true). The subscale scores range from 5 to 25 with an overall score from 25 to 125 points. Several studies have supported the reliability and validity of reported childhood trauma obtained with this instrument.
discernment, validity with structured trauma interviews and corroborative with independent data (24). Thresholds presented by Walker et al. (15) were used to construct groups with either form of maltreatment or no maltreatment. Child maltreatment was classified when threshold scores for emotional abuse (10), emotional neglect (15), physical abuse (8), physical neglect (8), and sexual abuse (8) were met. The CTQ-derived prevalence rates and mean-values of child maltreatment were compared to the German general population described by Iffland et al. (25).

**Assessment of Symptoms of Anxiety and Depression and Quality of Life**

Symptoms of anxiety and depression were assessed with participants completing the Hospital Anxiety and Depression Scale (HADS) (26). The HADS questionnaire is divided into subscales for anxiety (HADS-A) and depression (HADS-D), each containing seven questions for a maximum of 21 points per subscale. The higher score indicating a more severe anxiety or depression. Zigmond et al. (26) proposed a score >11 per subscale to be associated with significant anxiety or depression. A cut-off score of 8 or above for both HADS-A and HADS-D was validated, showing probable signs of anxiety or depression (27, 28). The World Health Organization Quality of Life [WHO-QoL-BREF (29)] was used to assess quality of life.

**Statistical Analysis**

IBM SPSS Statistics (version 28.0, IBM Corp., Armonk, New York) and Stata 13.0 (State Corp LP, College Station, Texas, USA) statistical software programs were used for statistical analysis. Continuous parameters are presented as median and interquartile range (Q25–Q75) or as mean and standard deviation (SD). Categorical variables are presented as number (n) and percent (%). Comparisons of continuous parameters were conducted using t-test or Mann-Whitney U-test (if not normally distributed or ordinal scaled) and comparison of categorical parameters by using Chi-square-test or fisher's exact test, unless indicated otherwise. Correlations of continuous and ordinal parameters were assessed using Pearson correlation coefficient. Parameters were CTQ-scores, lifestyle factors (exercise, drinks per week, and smoking intensity) and clinical parameters such as BMI, HADS-scores, QoL, 6MWD, and WHO FC. Logistic regression analysis was conducted to assess impact of CTQ-score on clinical outcome parameter WHO FC as surrogate for disease severity (WHO FC I and II vs. WHO FC III and IV was used as binary outcome). Further univariate logistic regression was conducted to assess impact of child maltreatment (any positive CTQ-subscore) on anxiety or depression disorder. Nagelkerke's R2 was determined to assess model quality. All tests were two-sided, p < 0.05 were considered statistically significant. P-values of multiple correlations were adjusted using the Benjamini–Hochberg-procedure.

**RESULTS**

This patient cohort was previously described in the PEPPAH-study (12). A total of 327 patients were approached in this study. Two hundred and seventeen patients (66%) agreed to participate and returned the questionnaires (Figure 1). Patient characteristics are shown in Table 1. The majority of patients were female (n = 155, 71%); median age was 56 (49-67) years. All patients were treated with PAH medications, most of them (47%) with dual combination therapy. Nearly all patients (96%) fell in the low or intermediate ERS risk score category. Patients with any form of child maltreatment were more likely to be active smokers, had a worse overall QoL and more anxiety and depression. Trends could be observed in 6MWD with more than 30 m difference in patients with or without any form of child maltreatment (Table 1). Disease severity indicated by ERS risk status, WHO FC and NTproBNP, hemodynamics at time of diagnosis, and PAH treatment did not differ between groups.

**Prevalence of Child Maltreatment in Patients With PAH**

In this study, child maltreatment with at least one subgroup above threshold was detected in fifty percent of the patients (Table 1). Emotional abuse and emotional neglect were about 2 times more frequent in patients with PAH than in the general population (Table 1; Figure 2). Patients with PAH had a significantly higher total CTQ score (p < 0.001), while physical neglect was more prevalent in the general German population (48.4 vs. 36.4%, p = 0.041) and physical abuse did not significantly differ between both groups (14.3 vs. 12.0%, p = 0.458). Sexual abuse was reported under 10% in both patients with PAH and the general population (Table 2).

**Correlation of CTQ Subscores on Quality of Life, Mental Health, Lifestyle, and Clinical Parameters**

Moderate associations between CTQ-scores, mental health, QoL, lifestyle factors, and clinical parameters could be observed (see...
TABLE 1 | Patient characteristics.

|                       | All patients n = 217 | Patients with any CTQ positive subscore n = 108 (50%) | Patients without any CTQ positive subscore n = 109 (50%) | p-value of group comparison |
|-----------------------|----------------------|------------------------------------------------------|-------------------------------------------------------|----------------------------|
| Age—years             | 56 (49-67)           | 55 (41-65)                                           | 57 (45-66)                                            | 0.422                      |
| Sex—female (%)        | 155 (71%)            | 74 (69%)                                             | 81 (74%)                                              | 0.345                      |
| BMI (kg/m²)           | 26 (23-31)           | 26 (23-31)                                           | 26 (23-31)                                            | 0.813                      |
| Time since PAH diagnosis (years) | 6 (3-11)          | 6 (2-11)                                             | 7 (4-13)                                              | 0.062                      |
| Diagnosis—n (%)       |                      |                                                      |                                                       |                            |
| - 1.1 IPAH            | 122 (66%)            | 68 (61%)                                             | 56 (51%)                                              | 0.233                      |
| - 1.2 HPAH            | 25 (12%)             | 13 (12%)                                             | 12 (11%)                                              |                            |
| - 1.4 Associated PAH  | 70 (32%)             | 29 (27%)                                             | 41 (38%)                                              |                            |
| WHO FC                |                      |                                                      |                                                       |                            |
| - I, n (%)            | 20 (9%)              | 7 (7%)                                               | 13 (12%)                                              | 0.439                      |
| - II, n (%)           | 92 (43%)             | 45 (42%)                                             | 47 (44%)                                              |                            |
| - III, n (%)          | 93 (43%)             | 51 (47%)                                             | 42 (39%)                                              |                            |
| - IV, n (%)           | 10 (5%)              | 5 (5%)                                               | 5 (5%)                                                |                            |
| ESC/ERS risk status—n (%) |                  |                                                      |                                                       |                            |
| - Low                 | 107 (50%)            | 52 (49%)                                             | 55 (52%)                                              | 0.799                      |
| - Intermediate        | 97 (46%)             | 51 (53%)                                             | 46 (47%)                                              |                            |
| - High                | 9 (4%)               | 4 (4%)                                               | 5 (5%)                                                |                            |
| 6MWD                  | 439 (353–521)        | 423 (339–502)                                        | 454 (371–539)                                         | 0.061                      |
| NT-proBNP (ng/l), n = 192 | 184 (86–517)   | 169 (74–419)                                         | 207 (104–568)                                         | 0.961                      |
| DLCO (% pred.), n = 138 | 62 (47-74)      | 64 (42-73)                                           | 61 (48-74)                                            | 0.844                      |
| paO₂, mmHg            | 67 (60–75)           | 67 (60–76)                                           | 67 (61–75)                                            | 0.788                      |
| Hemodynamics at diagnosis                                |                          |                                                      |                                                       |                            |
| - mPAP (mmHg)         | 48 (41-57)           | 48 (41-58)                                           | 49 (41-58)                                            | 0.651                      |
| - PAWP (mmHg)         | 9 (6-12)             | 9 (6-12)                                             | 9 (6-12)                                              | 0.794                      |
| - CI (l/min/m²)       | 2.4 (2.0–2.9)        | 2.4 (2.0–3.0)                                        | 2.4 (2.0–2.7)                                         | 0.284                      |
| - PVR (dyn·s·cm⁻⁵)    | 707 (501–947)        | 689 (505–951)                                        | 752 (498–927)                                         | 0.914                      |
| PH-therapy—n (%)      |                      |                                                      |                                                       |                            |
| - Monotherapy         | 44 (20%)             | 21 (19%)                                             | 23 (21%)                                              | 0.673                      |
| - Double combination therapy                               | 102 (47%)               | 54 (50%)                                             | 48 (44%)                                              |                            |
| - Triple combination therapy                               | 71 (33%)               | 33 (31%)                                             | 38 (35%)                                              |                            |
| Smoking status        |                      |                                                      |                                                       |                            |
| - Active, n (%)       | 24 (11%)             | 17 (16%)                                             | 7 (6%)                                                | 0.021                      |
| - Former, n (%)       | 31 (14%)             | 19 (18%)                                             | 12 (11%)                                              |                            |
| - Never, n (%)        | 162 (75%)            | 72 (67%)                                             | 90 (83%)                                              |                            |
| - Packyears           | 14 (5-25)            | 15 (6-23)                                            | 9 (4-33)                                              | 0.495                      |
| Alcohol drinking (drinks per week) | 0.8 ± 2.0         | 0.9 ± 2.5                                            | 0.8 ± 1.1                                             | 0.772                      |
| Exercise score (points) | 3 (2-4)              | 3 (2-3)                                              | 3 (2-4)                                               | 0.906                      |
| HADS-A (points)       | 6 (2-9)              | 7 (3-10)                                             | 5 (2-9)                                               | 0.034                      |
| HADS-D (points)       | 5 (2-8)              | 6 (3-9)                                              | 4 (2-7)                                               | 0.002                      |
| QoL-overall (points)  | 50 (38-75)           | 50 (38-63)                                           | 63 (44-75)                                            | 0.026                      |
| QoL-psych (points)    | 71 (56–79)           | 63 (50–79)                                           | 71 (63–83)                                            | 0.020                      |
| QoL-physical (points) | 57 (45-75)           | 57 (43-71)                                           | 64 (50-75)                                            | <0.001                     |
| QoL-social (points)   | 67 (58-83)           | 67 (58-83)                                           | 67 (50-75)                                            | 0.009                      |
| QoL-environment (points) | 78 (69-88)          | 75 (63-84)                                           | 78 (70-88)                                            | 0.012                      |

Continuous variables are stated as median and interquartile ranges (IQR) and categorical variables are stated as n and percent (%), unless indicated otherwise. All p-values were derived using t-test, unless indicated otherwise.

a Mean and SD because of distribution of the data.
b Non-parametric Mann–Whitney U-test because of ordinal scale of the variable.
c Chi²-test because of the categorical scale of the variable.

BMI, body mass index; QoL, quality of life; HADS-A, Hospital Anxiety and Depression Scale—anxiety; HADS-D, Hospital Anxiety and Depression Scale—Depression; I/HPAH, idiopathic or heritable pulmonary arterial hypertension; WHO FC, World Health Organization Functional Class; 6MWD, 6-min walking distance; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; DLCO, diffusion capacity of the lung for carbon monoxide; paO₂, mmHg, arterial paO₂; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary artery wedge pressure; CI, cardiac index; PVR, pulmonary vascular resistance; IQR, interquartile range. Statistically significant values as bold.
TABLE 2 | Scores and prevalence of child maltreatment in patients with PAH compared to German population.

| Item                        | PAH                  | German population (25) | p     |
|-----------------------------|----------------------|------------------------|-------|
|                             | n = 217              | n = 2,500              |       |
| **Comparison of CTQ-scores, Mean (SD)** |                      |                        |       |
| - CTQ-total score           | 41.84 ± 14.43        | 35.99 ± 10.48          | <0.001|
| - CTQ-emotional abuse       | 7.68 ± 4.00          | 6.51 ± 2.60            | <0.001|
| - CTQ-emotional neglect     | 9.58 ± 4.88          | 10.09 ± 4.23           | 0.093 |
| - CTQ-physical abuse        | 6.19 ± 2.83          | 5.88 ± 2.17            | 0.049 |
| - CTQ-physical neglect      | 7.18 ± 2.75          | 8.15 ± 3.02            | <0.001|
| - CTQ-sexual abuse          | 5.54 ± 2.24          | 5.45 ± 1.66            | 0.458 |
| **Comparison of CTQ-categories, n (%)** |                      |                        |       |
| - CTQ-emotional abuse       | 43 (19.8%)           | 254 (10.2%)            | <0.001|
| - CTQ-emotional neglect     | 42 (19.4%)           | 348 (13.9%)            | 0.078 |
| - CTQ-physical abuse        | 31 (14.3%)           | 301 (12.0%)            | 0.458 |
| - CTQ-physical neglect      | 79 (36.4%)           | 1,210 (48.4%)          | 0.041 |
| - CTQ-sexual abuse          | 14 (6.5%)            | 156 (6.2%)             | 0.920 |

Continuous variables are stated as mean and standard deviation and categorical variables are stated as n and percent (%).

CTQ, childhood trauma questionnaire; PAH, pulmonary arterial hypertension; SD, standard deviation; Statistically significant values as bold.

Table 3). Higher CTQ emotional-, physical, or total scores were correlated with higher HADS depression and anxiety scores ($r = 0.201–0.401$, $p < 0.001$) while being negatively correlated with QoL ($r = −0.200$ to $−0.315$, $p < 0.001$). History of smoking and WHO FC were positively correlated with emotional and physical CTQ-scores ($r = 0.113–0.216$). Total CTQ-scores were negatively correlated to 6MWD ($r = −0.145$ to $r = −0.204$, $p < 0.005$) whereas exercise and drinks per week were not significantly related. There were no significant association between CTQ-sexual abuse and any evaluated parameter.

Impact of CTQ on Disease Severity and Mental Health

Univariate logistic regression analysis on disease severity (WHO FC I+II vs. WHO FC III+IV) revealed a significant impact of CTQ-total score with an OR of 1.022 (95%-CI: 1.001–1.042, $p = 0.035$) while the model describes 2.9% of the independent variable. Further univariate regression analysis showed that patients with reported emotional neglect had a 6.8% higher chance (95%-CI: 1.009–1.131, $p = 0.023$) of being in WHO FC III or IV per CTQ point increase. Model accuracy was 3.3%. Impact of any positive CTQ-subscore on anxiety had an OR of 1.678
TABLE 3 | Correlations of CTQ-scores in PAH with HADS, QoL, Lifestyle and 6MWD, and WHO FC.

|                       | HADS-D  | HADS-A  | QoL   | BMI    | Exercise | Drinks | Smoking | WHO FC | 6MWD |
|-----------------------|---------|---------|-------|--------|----------|--------|---------|--------|-------|
| CTQ-total score       | 0.388** | 0.351** | −0.315** | 0.158* | −0.068 | −0.071 | 0.188* | 0.186* | −0.192* |
| CTQ-emotional abuse   | 0.388** | 0.401** | −0.302** | 0.126 | −0.039 | −0.027 | 0.181** | 0.125 | −0.174* |
| CTQ-emotional neglect | 0.316** | 0.255** | −0.308** | 0.121 | −0.056 | −0.082 | 0.113 | 0.210* | −0.145* |
| CTQ-physical abuse    | 0.262** | 0.268** | −0.200** | 0.139* | −0.081 | −0.066 | 0.157* | 0.118* | −0.146* |
| CTQ-physical neglect  | 0.251** | 0.204*  | −0.269* | 0.131 | −0.041 | −0.088 | 0.216* | 0.192* | −0.204* |
| CTQ-sexual abuse      | 0.112   | 0.106   | −0.056 | 0.123 | 0.123   | 0.033  | 0.001  | 0.021  | 0.049  | −0.097 |

Pearson correlation coefficient. Statistically significant values are marked using asterisk, **p < 0.001; *p < 0.05.
BMI, body mass index; CTQ, childhood trauma questionnaire; QoL, quality of life; HADS-A, Hospital Anxiety and Depression Scale—anxiety; HADS-D, Hospital Anxiety and Depression Scale—depression; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization Functional Class; 6MWD, 6-min walking distance.

(95%-CI: 0.788–3.574, p = 0.179) while impact on depression showed an OR of 2.761 (95%-CI: 1.369–5.209, p = 0.004) while model accuracy was 1.5 and 6%, respectively.

DISCUSSION

To the best of our knowledge this is the first study to assess the prevalence of child maltreatment in patients with PAH. Patients with PAH had a higher overall CTQ-score with fifty percent of our patients exceeding the threshold for any subscore of child maltreatment. In these patients, moderate associations between CTQ-scores and QoL, anxiety and depression, WHO FC, and 6MWD could be detected. Higher prevalence of CTQ-scores were mainly driven by higher subscores in emotional abuse or physical abuse. This is in line with previous observations from patients with congenital heart disease (19). While absolute scores were higher in patients with PAH, both groups reported only moderately elevated scores on the scale of 5–25 points per subscore (as seen in Figure 2). Inversely physical neglect was comparatively more frequent in the general population than in patients with PAH. It has been discussed that elderly who experienced privation of (post-)war year were more likely to report physical neglect (25). With comparatively weak psychometric properties and weak internal consistency, comparisons for the physical neglect subscale discussion on impact can only be held cautiously.

Several severe long-term consequences of child maltreatment have been studied and suggested. Ranging from mentioned physical health, psychological to behavioral, and societal consequences. Most children who experienced child maltreatment are often affected by many other adversities such as domestic violence, poverty, and parental substance abuse (30).

Child maltreatment poses a higher risk on the development of mental disorders such as depression (31–34). Olsson et al. have recently demonstrated a higher prevalence of mental disorders in patients with PAH. Our findings indicate a correlation between higher CTQ scores and higher HADS depression and anxiety scores. Gamble et al. (35) in as early as 2006 had described the correlation between childhood trauma and severity of anxiety and depression. Similarly, we demonstrated impact of child maltreatment on the diagnosis of depression, which is in line with these previous studies. Several studies examining impact of child maltreatment on disease outcomes saw attenuation of the relationship between child maltreatment and disease when adjusting for mental disorder (36). Our data supports existing evidence in indicating that child maltreatment is a risk factor for mental disorders which themselves may be mediators for disease severity of PAH (36).

QoL contributes to the evaluation of emerging PAH treatments as well as disease course. QoL in patients with PAH is severely impaired by clinical symptoms as well as emotional domain (20, 37). Mathai et al. (38) have found QoL to be a predictor of outcomes in PAH and thus a target for therapeutic interventions. Child maltreatment in patients with PAH correlate with worse QoL. This is in line previous studies such as Corso et al. who demonstrated significant and sustained losses of QoL in adulthood of persons who experienced child maltreatment (39, 40).

Several studies have demonstrated association between child maltreatment and cardiometabolic diseases such as systemic hypertension, ischemic heart disease, and chronic heart disease (41, 42). Many authors examined child maltreatment as a composite measure of adversity and reported a dose-response relationship between number of childhood adversities and heightened risk for cardiometabolic diseases. Overall, CTQ scores were associated with disease severity measured by WHO FC. In a subscore analysis of our study, we found that patients with higher scores in emotional neglect had a significantly higher chance of being in a higher WHO FC per CTQ point increase. While this impact might suggest negative influence on disease course, morbidity, and mortality model accuracy is comparatively low. Clinical signs of right heart failure, 6MWD, NT-proBNP/BNP, and WHO FC are strong indicators of disease severity and risk status in patients with PAH (23). Arguably these somatic factors play a more prominent role on disease severity with a minor role of child maltreatment and by association mental disorders.

Limitations

Our paper has strength and limitations. Data for childhood maltreatment, mental health and QoL were derived using a self-administered, paper-based questionnaire. Reliable measurements of prevalence and severity of child maltreatment have yet relied
on self-reports, showing discrepancies of rates compared to reports of child-protection agencies (43, 44). Median global prevalence rates differ substantially by maltreatment type, gender and by continent with varying number of studies and available data (45). Only two German PH-centers were involved in this study which might cause selection bias. This study was carried out between September 2019 and March 2020. In January, the Corona virus pandemic hit Germany and this study didn’t control for any possible impact on mental disease during this time. Of note, Park et al. (46) have studied effects on first waves of corona virus pandemic on a subsample of this cohort and found minor changes in mental health due to the corona virus pandemic. However, a strength is relatively large sample size of PAH patients given that PAH is a rare disease as both participating centers are large university-based tertiary-level referral centers.

### CONCLUSION

In the present study, child maltreatment, in particular, subscores for emotional abuse and physical abuse was more prevalent in patients with PAH than in the general population. The presence of child maltreatment was associated with a higher likelihood of anxiety and depression and reduction in QoL. Child maltreatment in patients with PAH might play a role in disease severity. With wide ranges of long-term consequences of child maltreatment, screening for a history of child maltreatment can help physicians in assessment of patients’ needs and treatment options. This should be taken into consideration in addition to more widely acknowledged impact of mental disorders and QoL on PAH. Psychosocial interventions as a treatment approach have been proven effective in patients with a history of child maltreatment (47–49). Integrating past experiences and psychological problems in the care and treatment of patients with PAH is recommended. The lasting consequences of child maltreatment warrant further investigation.

### DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

### ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Hannover Medical School and University of Giessen and Marburg. The patients/participants provided their written informed consent to participate in this study.

### AUTHOR CONTRIBUTIONS

DHP was responsible for study design, implementation of the study, data collection, data interpretation, and drafting the manuscript. TM was responsible for data collection and revising the manuscript. KK was responsible for study design, data interpretation, and revising the manuscript. JK was responsible for data interpretation and revising the manuscript. MR, HG, and HAG were responsible for implementation of the study and critically revising the manuscript. MH was responsible for implementation of the study, data interpretation, and critically revising the manuscript. KO was responsible for study design, implementation of the study, data interpretation, and critically revising the manuscript. JF was responsible for study design, implementation of the study, data collection, statistical analysis, data interpretation, and drafting the manuscript. All authors contributed to the article and approved the submitted version.

### ACKNOWLEDGMENTS

We wish to thank all patients who participated in this project.

### REFERENCES

1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. (2015) 46:903–75. doi: 10.1183/13993003.01032-2015

2. Hoeper MM, Humbert M, Souza R, Iderees M, Kawut SM, Siwa-Hahne K, et al. A global view of pulmonary hypertension. Lancet Respir Med. (2016) 4:306–22. doi: 10.1016/S2216-2600(15)00543-3

3. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest. (2004) 126:1452–9. doi: 10.1378/chest.126.5.1452

4. Fuge J, Park DH, von Lengerke T, Richter MJ, Gall H, Ghofrani A, et al. Impact of pulmonary arterial hypertension on employment, work productivity and quality of life - results of a cross-sectional multi-center study. Front Psychiatry. (2021). doi: 10.3389/fpsyt.2021.781532

5. Sommer N, Ghofrani HA, Pak O, Bonnet S, Provencher S, Sibton O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. (2021) 178:6–30. doi: 10.1111/bph.15016

6. Armstrong I, Billings C, Kiely DG, Yorke J, Harries C, Clayton S, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med. (2019) 19:67. doi: 10.1186/s12890-019-0827-5

7. Zhai Z, Zhou X, Zhang S, Xie W, Wan J, Kuang T, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey. Medicine (Baltimore). (2017) 96:e6783. doi: 10.1097/MD.0000000000006783

8. Guillemin L, Armstrong I, Aldighetti R, Howard LS, Ryffenius H, Fischer A, et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev. (2013) 22:535–42. doi: 10.1183/09059180.0005713

9. Von Visger TT, Kuntz KK, Phillips GS, Yildiz VO, Sood N. Quality of life and psychological symptoms in patients with pulmonary hypertension. Heart Lung. (2018) 47:115–21. doi: 10.1016/j.hrtlng.2017.12.004

58
48. Domhardt M, Baumeister H. Psychotherapy of adjustment disorders: current state and future directions. World J Biol Psychiatry. (2018) 19:S21–S35. doi: 10.1080/15622975.2018.1467041
49. Goodnight JRM, Ragdale KA, Rauch SAM, Rothbaum BO. Psychotherapy for PTSD: an evidence-based guide to a theranostic approach to treatment. Prog Neuropsychopharmacol Biol Psychiatry. (2019) 88:418–26. doi: 10.1016/j.pnpbp.2018.05.006

Conflict of Interest: DHP has received honoraria for lectures and/or consultations from Janssen. KK has received honoraria for consultations and/or lectures from Eli Lilly, Janssen, Lundbeck, Neuraxpharm, Otsuka, Pfizer, Servier, Schwabe, Takeda, and Trommsdorff/Ferrer, Alexion, and CannaXan (advisory board). HG has received personal fees from Actelion, personal fees from AstraZeneca, personal fees from Bayer, personal fees from BMS, personal fees from GSK, personal fees from Janssen-Cilag, personal fees from Lilly, personal fees from MSD, personal fees from Novartis, personal fees from OMT, personal fees from Pfizer, personal fees from United Therapeutics, outside the submitted work. HG has received fees from Actelion, Bayer, Gilead, GSK, MSD, Pfizer, and United Therapeutics, outside the present work. HAG has received honoraria for lectures and/or consultations from Actelion, Bayer, GSK, Janssen, MSD and Pfizer, all outside the present study. KO has received honoraria for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, United Therapeutics and Pfizer, all outside the present study.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Park, Meltendorf, Kahl, Kamp, Richter, Gall, Ghofrani, Hoeper, Olsson and Fuge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.